Evidence map›Paper›PMID 38803016›Full record

ReviewPeriodontology 20002025

Instructions for the use of L-PRF in different clinical indications.

M Quirynen, J Blanco, H-L Wang, N Donos, A Temmerman, A Castro, N Pinto

Abstract readReview
In one paragraph

Review in Periodontology 2000, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Apple-Derived Vesicles Orchestrate Bone Regeneration:International journal of molecular sciences · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

M QuirynenDepartment of Oral Health Sciences, Katholieke Universiteit Leuven, Dentistry (Periodontology), University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-8253-3908
J BlancoDepartment of Department of Stomatology, Unit of Periodontology, Santiago de Compostela University, Santiago de Compostela, Spain.ORCID 0000-0001-9251-513X
H-L WangDepartment of Periodontics and Oral Medicine, School of Dentistry, The University of Michigan, Michigan, USA.ORCID 0000-0003-4238-1799
N DonosCentre for Oral Clinical Research, Institute of Dentistry, Faculty of Medicine and Dentistry, Queen Mary University of London (QMUL), London, UK.ORCID 0000-0002-4117-9073
A TemmermanDepartment of Oral Health Sciences, Katholieke Universiteit Leuven, Dentistry (Periodontology), University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0003-1513-2236
A CastroDepartment of Oral Health Sciences, Katholieke Universiteit Leuven, Dentistry (Periodontology), University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-5329-3113
N PintoCenter of Translational Medicine, Faculty of Medicine, Universidad de la Frontera, Temuco, Chile.ORCID 0000-0002-4676-3359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous platelet concentrates (APCs) have demonstrated clear benefits across various clinical applications, including alveolar ridge preservation, guided tissue regeneration, guided bone regeneration, sinus floor elevation (both lateral window approach and transcrestal technique), endodontic surgery, the treatment of medication-related osteonecrosis of the jaw bones, and periodontal plastic surgery. To ensure an optimal clinical outcome, clinicians must adhere strictly to the protocol to prepare the APCs and, especially follow evidence-based surgical guidelines, often simple but crucial, to minimize the likelihood of errors. The majority of clinical trials reported on second-generation APCs [the leukocyte- and platelet-rich fibrin (L-PRF) family, including its modifications (A-PRF, A-PRF+, CGF, T-PRF, H-PRF, etc.)]. These second-generation APCs offer additional benefits compared to the first-generation APCs, making them the preferred choice for the development of clinical recommendations. These recommendations have been formulated through a meticulous examination of the available clinical data and the clinical experience of the authors of this paper.

Indexed as

Blood PlateletsPlatelet-Rich FibrinHumansLeukocytesPractice Guidelines as Topicalveolar ridge preservationautologous platelet concentratesflowchartsguided bone regenerationguided tissue regenerationintra‐bony defectsmedication‐related osteonecrosis of the jaw bonesplastic periodontal surgerysinus floor elevation (lateral window technique, transcrestal technique)

Identifiers

PMID38803016
PMCPMC11808411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.